Masako Ura

TL;DR: Capecitabine, which is finally converted to 5-FU by dThdPase in tumours, should be much safer and more effective than5-FU, and this was indeed the case in the HCT116 human colon cancer and the MX-1 breast cancer xenograft models.

TL;DR: The therapeutic benefit of 5′-dFUrd would be improved by its use in combination with the cytokines, and the cytokine mixture increased TdR Pase activity by up to 47 times and greatly induced its mRNA expression in the cancer cell lines.

TL;DR: In tests with various human cancer xenograft models, capecitabine was more efficacious at wider dose ranges than either 5-FU or 5'-DFUR and was significantly less toxic to the intestinal tract than the others in monkeys.

TL;DR: It was revealed that the most important factors that determine the selective production of 5-FU in tumor tissue after capecitabine administration are tumor-specific activation by dThdPase, the nonlinear elimination of5-FU by DPD in tumor tissues, and the blood flow rate in tumors.

TL;DR: The results indicate that the efficacy of DMDC may be predicted by measuring the activity of Cyd deaminase in tumor tissues before treatment starts and that DMDC might be exploited in a new treatment modality: tumor enzyme-driven cancer chemotherapy.